Sastasundar Ventures Limited (IN:SASTASUNDR)
:SASTASUNDR
Top Page
Sastasundar Ventures Limited
(SASTASUNDR)
Select Model
Select Model
Rating:47Neutral
Price Target:
₹257.00
▼(-17.59% Downside)
Action:ReiteratedDate:09/11/25
The overall stock score of 47 reflects significant financial challenges, including declining revenues and persistent losses. Technical analysis shows neutral to bearish momentum, while valuation metrics are unattractive due to negative earnings. The absence of earnings call data and corporate events limits further insights.
Positive Factors
Low leverage / strong equity base
A high equity ratio and low debt reduce financial risk and give the company a longer runway to invest or restructure without immediate refinancing pressure. This durable balance-sheet strength supports strategic initiatives and cushions cyclical shocks.
Negative Factors
Declining revenues
A material year-over-year revenue decline weakens scale economics and makes fixed-cost absorption harder, pressuring margins and investment capacity. Sustained top-line shrinkage undermines long-term profitability and market positioning if not reversed.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong equity base
A high equity ratio and low debt reduce financial risk and give the company a longer runway to invest or restructure without immediate refinancing pressure. This durable balance-sheet strength supports strategic initiatives and cushions cyclical shocks.
Read all positive factors
Sastasundar Ventures Limited (SASTASUNDR) vs. iShares MSCI India ETF (INDA)
Market Cap
₹8.31B
Dividend YieldN/A
Average Volume (3M)4.89K
Price to Earnings (P/E)207.7
Beta (1Y)0.87
Revenue Growth-3.97%
EPS Growth96.73%
CountryIN
Employees941
SectorConsumer Defensive
Sector Strength42
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.35
Shares Outstanding31,810,500
10 Day Avg. Volume1,551
30 Day Avg. Volume4,895
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.20
Price to Sales (P/S)0.74
P/FCF Ratio-29.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sastasundar Ventures Limited Business Overview & Revenue Model
Company Description
Sastasundar Ventures Limited operates a digital network of healthcare in India. It finances loans, and invests in shares and securities, as well as provides financial consultancy, professional fees, wealth management, financial planning, distribut...
How the Company Makes Money
Publicly available, reliable details sufficient to describe Sastasundar Ventures Limited’s current, specific revenue model and key revenue streams (e.g., segment-wise revenue mix, monetization mechanics, and material partnerships contributing to e...
Sastasundar Ventures Limited Financial Statement Overview
Summary
Income Statement
40
Negative
Balance Sheet
60
Neutral
Cash Flow
35
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Jun 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.50B | 10.90B | 13.56B | 10.38B | 6.30B | 5.46B |
| Gross Profit | 790.68M | 721.21M | 1.20B | 711.54M | 445.35M | 513.28M |
| EBITDA | -268.79M | -1.87B | -203.51M | -1.13B | 11.22B | -109.58M |
| Net Income | -20.46M | -911.67M | 88.83M | -722.11M | 6.27B | -104.01M |
Balance Sheet | ||||||
| Total Assets | 10.08B | 9.74B | 11.50B | 12.06B | 12.78B | 2.93B |
| Cash, Cash Equivalents and Short-Term Investments | 240.06M | 124.44M | 3.95B | 2.08B | 2.12B | 124.49M |
| Total Debt | 51.49M | 11.88M | 38.83M | 93.25M | 18.53M | 152.02M |
| Total Liabilities | 1.32B | 1.10B | 1.50B | 2.12B | 1.84B | 634.32M |
| Stockholders Equity | 6.81B | 6.70B | 7.62B | 7.53B | 8.27B | 2.00B |
Cash Flow | ||||||
| Free Cash Flow | -326.00M | -276.65M | 239.34M | -1.31B | -2.12B | -314.92M |
| Operating Cash Flow | -271.35M | -173.09M | 381.65M | -1.12B | -2.07B | -305.08M |
| Investing Cash Flow | 406.47M | -11.34M | -339.27M | 1.33B | 2.20B | 213.71M |
| Financing Cash Flow | -19.52M | -4.43M | -23.52M | -18.33M | -114.22M | 37.26M |
Sastasundar Ventures Limited Technical Analysis
Negative
311.85
Price Trends
288.23
Negative
297.38
Negative
295.38
Negative
Market Momentum
-4.12
Positive
36.36
Neutral
15.18
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SASTASUNDR, the sentiment is Negative. The current price of 311.85 is above the 20-day moving average (MA) of 278.50, above the 50-day MA of 288.23, and above the 200-day MA of 295.38, indicating a bearish trend. The MACD of -4.12 indicates Positive momentum. The RSI at 36.36 is Neutral, neither overbought nor oversold. The STOCH value of 15.18 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SASTASUNDR.
Sastasundar Ventures Limited Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
62 Neutral | ₹100.58B | 41.81 | ― | ― | 4.94% | 94.22% | |
47 Neutral | ₹8.31B | 207.74 | ― | ― | -3.97% | 96.73% |
* Consumer Defensive Sector Average
IN:SASTASUNDR
Sastasundar Ventures Limited
261.25
7.85
3.10%
IN:MEDPLUS
MedPlus Health Services Ltd.
837.75
87.55
11.67%
Sastasundar Ventures Limited Corporate Events
Health X Platform Unit Clears Envision Deal and Merger Framework
Feb 27, 2026
Health X Platform Limited has disclosed that the board of its material subsidiary, Sastasundar Healthbuddy Limited, has approved a tripartite agreement with the parent company and Envision India Fund, a Mauritius-based qualified institutional buye...
Health X Platform Sets Merger Path With Subsidiary as Envision Enters Cap Table
Feb 27, 2026
Health X Platform Limited, formerly Sastasundar Ventures Limited, has a key operating arm in Sastasundar Healthbuddy Limited, its material subsidiary engaged in healthcare platform activities. Its shareholder base in the subsidiary includes strate...
Envision India Fund to Acquire Mitsubishi’s 4.68% Stake in Sastasundar Healthbuddy
Feb 25, 2026
Sastasundar Healthbuddy Limited, a material subsidiary of Health X Platform Limited, has entered into a share purchase agreement with Mitsubishi Corporation and Envision India Fund for a secondary share transaction. The deal involves the sale of 1...
Sastasundar Ventures Rebrands as Health X Platform Limited After Regulatory Nod
Feb 20, 2026
Health X Platform Limited, previously Sastasundar Ventures Limited, has received formal approval from the Registrar of Companies and the Ministry of Corporate Affairs to change its corporate name. The company remains a publicly listed entity in In...
Sastasundar Ventures Sets 9 February Earnings Call for Q3 and Nine-Month FY26 Results
Feb 2, 2026
Sastasundar Ventures Limited has scheduled an earnings conference call with analysts and investors on Monday, 9 February 2026 at 4:00 p.m. IST to discuss its financial performance and business updates for the third quarter and nine-month period en...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.